Information Provided By: 
Fly News Breaks for April 18, 2018
RIGL
Apr 18, 2018 | 07:08 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Rigel Pharmaceuticals to $8 after the FDA approved Tavalisse for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The broad label puts Tavalisse firmly in the second-line therapy sandbox, Pantginis tells investors in a research note. He keeps a Buy rating on Rigel shares.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
